Last $3.63 USD
Change Today -0.08 / -2.16%
Volume 386.6K
CERS On Other Exchanges
CERS is not on other exchanges.
As of 8:10 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

cerus corp (CERS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $8.00
52 Week Low
07/28/14 - $3.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CERUS CORP (CERS)

Related News

No related news articles were found.

cerus corp (CERS) Related Businessweek News

No Related Businessweek News Found

cerus corp (CERS) Details

Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

115 Employees
Last Reported Date: 03/7/14
Founded in 1991

cerus corp (CERS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $495.8K
Co-Founder, Chief Medical Officer, Chief Scie...
Total Annual Compensation: $398.2K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $277.0K
President of Cerus Europe
Total Annual Compensation: $304.4K
Senior Vice President of Regulatory Affairs, ...
Total Annual Compensation: $315.4K
Compensation as of Fiscal Year 2013.

cerus corp (CERS) Key Developments

Cerus Submits Final Module in Premarket Approval Application Process for INTERCEPT Platelets

Cerus Corporation announced that it has submitted the third and final module for its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA), for review of the INTERCEPT Blood System for platelets. The INTERCEPT platelet submission was completed at the end of the second quarter as projected in Cerus' regulatory timeline.

Cerus Corporation Secures $30 Million Growth Capital Credit Facility from Oxford Finance LLC

Cerus Corporation announced that it has entered into a $30 million growth capital credit facility with Oxford Finance LLC. Cerus received an immediate $10 million loan at closing on June 30, 2014. The Company has the option to draw another $10 million upon approval of its U.S. Premarket Approval (PMA) submissions for the INTERCEPT Blood System for either platelets or plasma. The approval also triggers a third $10 million tranche which is available at the Company's option between July 1, 2015 and December 31, 2015, subject to achievement of certain specified consolidated revenue milestones.

Cerus Corporation Approves Amendment to Amended and Restated Certificate of Incorporation

Cerus Corporation announced that at its annual general meeting held on June 11, 2014, the company's stockholders approved the amendment to the company's Amended and Restated Certificate of Incorporation to increase the authorized number of shares of Common Stock from 112,500,000 shares to 225,000,000 shares.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERS:US $3.63 USD -0.08

CERS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $1.97 USD +0.01
Cytori Therapeutics Inc $2.16 USD +0.03
Pluristem Therapeutics Inc $2.85 USD -0.01
Stereotaxis Inc $3.40 USD +0.08
SurModics Inc $19.83 USD +0.21
View Industry Companies

Industry Analysis


Industry Average

Valuation CERS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.1x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERUS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at